Novartis Announces Trial on Presymptomatic AD Patients

Repeated failures in Phase III clinical trials for ALS and Alzheimer’s disease are driving researchers and drug developers to seek approaches to intervene earlier in the course of disease. Significant research efforts are targeted at identifying early diagnostic biomarkers to enable earlier treatment (see June 2014 News). Now, Novartis is trying to succeed where others have failed by testing two new AD therapies in presymptomatic patients. They will begin testing two new AD therapies, an immunotherapy and a beta-secretase (BACE) inhibitor, to prevent buildup of amyloid proteins in patients with two copies of the APoE4 gene, which increases the risk of developing disease. This breakthrough study is slated to begin in early 2015.

Repeated failures in Phase III clinical trials for ALS and Alzheimer’s disease are driving researchers and drug developers to seek approaches to intervene earlier in the course of disease. Significant research efforts are targeted at identifying early diagnostic biomarkers to enable earlier treatment (see June 2014 News). Now, Novartis is trying to succeed where others have failed by testing two new AD therapies in presymptomatic patients. They will begin testing two new AD therapies, an immunotherapy and a beta-secretase (BACE) inhibitor, to prevent buildup of amyloid proteins in patients with two copies of the APoE4 gene, which increases the risk of developing disease. This breakthrough study is slated to begin in early 2015.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail